Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Mortality: a neglected outcome in OCS-treated severe asthma

Arnaud Bourdin, Nicolas Molinari, Isabelle Vachier, Laurie Pahus, Carey Suehs, Pascal Chanez
European Respiratory Journal 2017 50: 1701486; DOI: 10.1183/13993003.01486-2017
Arnaud Bourdin
1Dept of Respiratory Diseases, Montpellier University Hospitals, Hôpital Arnaud de Villeneuve, Montpellier, France
2PhyMedExp (INSERM U 1046, CNRS UMR9214), Université de Montpellier, Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Molinari
3Dept of Medical Information, Montpellier University Hospitals, Hôpital La Colombière, Montpellier, France
4Institut Montpelliérain Alexander Grothendieck, CNRS, Université de Montpellier, Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabelle Vachier
1Dept of Respiratory Diseases, Montpellier University Hospitals, Hôpital Arnaud de Villeneuve, Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurie Pahus
5Assistance Publique - Hôpitaux de Marseille, Clinique des bronches, allergies et sommeil, Hôpital Nord, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carey Suehs
1Dept of Respiratory Diseases, Montpellier University Hospitals, Hôpital Arnaud de Villeneuve, Montpellier, France
3Dept of Medical Information, Montpellier University Hospitals, Hôpital La Colombière, Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carey Suehs
Pascal Chanez
5Assistance Publique - Hôpitaux de Marseille, Clinique des bronches, allergies et sommeil, Hôpital Nord, Marseille, France
6Laboratoire Adhésion et Inflammation (LAI). INSERM U1067/CNRS UMR7333 Aix Marseille University Marseille, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pascal.chanez@univ-amu.fr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Findings from a long-term severe asthma cohort indicate mortality is a critical issue for OCS-dependent patients http://ow.ly/rO8e30fZrPo

To the Editor:

Severe asthma, especially if associated with a T2 phenotype, often responds well to new emerging therapies, which have led to a reduction in the use of systemic oral corticosteroids (OCS) [1]. However, OCS-dependent patients still exist and are affected by the well-known (and potentially severe) side effects of such dependency. Longitudinal data that document the outcomes, including death, for these patients are lacking [2]. Here, we present our findings from a long-term severe asthma cohort, which indicate that mortality is a critical issue for these patients.

In this prospective study of real-life asthma management in an expert centre devoted to severe asthma, 52 patients were enrolled in a 20-year observational study (starting in 1994) (IRB 2017_CLER-MTP_07-028). Exclusion criteria eliminated patients who had successful OCS-weaning trials in Year 1 (with no exacerbations during the year) and for whom environmental/adherence factors might have influenced OCS use.

Figure 1 shows patient characteristics and outcomes. Over 20 years, 26 patients died (50%), with mortality attributable to a fatal asthma episode (death in a medical unit confirmed as a fatal asthma episode, or the health care provider overseeing a fatal event attributed the cause of death to asthma) in 10 patients. The median number of years until death was nine (interquartile range (IQR) 25–75: 3–13, range 1–19), and this was similar between fatal asthma cases and others. Overall mortality predictors were baseline poor asthma control and the number of exacerbations during Year 1. The 50% death rate represented a significant increase in mortality compared to the expected survival rate adjusted for location (French department), age, and gender. The relative survival rate (RSR) was 0.778 with a 95% CI of 0.567–0.990, which corresponds to an absolute adjusted excess risk of death of ∼22%. For comparison, the 15-year RSR after aortic valve replacement has been estimated to be 0.749 [3]; the 10-year RSR for diabetes, 0.695 [4]; and the 20-year RSRs for melanoma or cancers of the uterus, testes or thyroid range from 0.73–0.963 [5, 6].

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Patient characteristics and outcome flowchart during the 20-year study period. Bold font denotes the best prognosis. BMI: body mass index; FEV1: % predicted forced expiratory volume in 1 s; OCS: oral corticosteroid; ICU: intensive care unit; GINA: Global Initiative for Asthma.

Regarding the 26 patients who were alive at Year 20, asthma was considered to be moderate in one (Global Initiative for Asthma (GINA) treatment step 4) and severe in 25 (GINA treatment step 5). Ten (38.5%) had severe comorbidities, among which, six were directly attributable to OCS. At Year 20, 10 patients were still OCS-dependent (8.8±12.8 mg·day−1). The OCS-dependent patients had two or more exacerbations per year, with two patients requiring repeated hospitalisation. Omalizumab was maintained in two patients, and three patients were treated with an investigational drug. Among the 15 non-OCS-dependent patients, 11 remained uncontrolled (including eight patients with two or more exacerbations per year). Four patients had asthma that remained well controlled, three of whom nevertheless had severe comorbidities.

In this 20-year study, we provide evidence for excess mortality among OCS-treated severe asthma patients that rivals that of other chronic diseases and certain cancers. Furthermore, only a small fraction of survivors achieved control of the condition. In contrast, the majority of 20-year survivors presented a mix of severe comorbidities associated with high exacerbation rates. These observations underline the continuing need for research and treatment discovery in severe asthma [7–9].

Disclosures

Supplementary Material

A. Bourdin ERJ-01486-2017_Bourdin

P. Chanez ERJ-01486-2017_Chanez

Footnotes

  • Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

  • Received May 23, 2017.
  • Accepted September 5, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    1. Chung KF,
    2. Wenzel SE,
    3. Brozek JL
    , et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Levy ML,
    2. Winter R
    . Asthma deaths: what now? Thorax 2015; 70: 209–210.
    OpenUrlFREE Full Text
  3. ↵
    1. Kvidal P,
    2. Bergström R,
    3. Hörte LG
    , et al. Observed and relative survival after aortic valve replacement. J Am Coll Cardiol 2000; 35: 747–756.
    OpenUrlFREE Full Text
  4. ↵
    1. Sasaki A
    . Assessment of the new criteria for diabetes mellitus according to 10-year relative survival rates. Diabetologia 1981; 20: 195–198.
    OpenUrlPubMedWeb of Science
  5. ↵
    1. Houterman S
    . Higher long-term cancer survival rates in southeastern Netherlands using up-to-date period analysis. Ann Oncol 2006; 17: 709–712.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Brenner H
    . Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 2002; 360: 1131–1135.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Nair P,
    2. Wenzel S,
    3. Rabe KF
    , et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 2017; 376: 2448–2458.
    OpenUrl
    1. Bel EH,
    2. Wenzel SE,
    3. Thompson PJ
    , et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371: 1189–1197.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Wells AU
    . Corticosteroid induced osteoporosis in severe menstrual asthma. Steroid sparing drugs may be useful. BMJ 1992; 305: 413–415.
    OpenUrlFREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 50 Issue 5 Table of Contents
European Respiratory Journal: 50 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Mortality: a neglected outcome in OCS-treated severe asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Mortality: a neglected outcome in OCS-treated severe asthma
Arnaud Bourdin, Nicolas Molinari, Isabelle Vachier, Laurie Pahus, Carey Suehs, Pascal Chanez
European Respiratory Journal Nov 2017, 50 (5) 1701486; DOI: 10.1183/13993003.01486-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Mortality: a neglected outcome in OCS-treated severe asthma
Arnaud Bourdin, Nicolas Molinari, Isabelle Vachier, Laurie Pahus, Carey Suehs, Pascal Chanez
European Respiratory Journal Nov 2017, 50 (5) 1701486; DOI: 10.1183/13993003.01486-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Carbon footprint of respiratory treatments
  • ERS/ATS standards on lung function test interpretation: some limitations
  • Reply: ERS/ATS standards on lung function test interpretation: some limitations
Show more Agora

Research letters

  • Carbon footprint of respiratory treatments
  • ERS/ATS standards on lung function test interpretation: some limitations
  • Reply: ERS/ATS standards on lung function test interpretation: some limitations
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society